» Articles » PMID: 27022308

Kozhikode Criteria for Diagnosing Systemic Lupus Erythematosus As a Hematological Disorder

Overview
Journal J Blood Med
Publisher Dove Medical Press
Specialty Hematology
Date 2016 Mar 30
PMID 27022308
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disease in which cells and tissues undergo damage mediated by tissue-binding autoantibodies. At its onset, it may involve one organ alone or more than one organ simultaneously; over a time, additional manifestations due to the involvement of other organs may occur. Our observations have confirmed that hematological manifestations are the commonest initial presentation in SLE. The criteria used till 2012 was the American College of Rheumatology (ACR) criteria, which is only a classification criterion and not really for diagnosis; if we rely on ACR criteria, the diagnosis is often delayed. Time required for satisfying all four of the eleven criteria is variable and prolonged. Moreover, hematological manifestations are underrepresented in the ACR criteria. Based on the clinical observations made on patients evaluated in a tertiary center in North Kerala, an alternate diagnostic criterion named the Kozhikode criteria was proposed, especially for the diagnosis of SLE when it presents with hematological manifestations alone. The present study was an attempt to validate the same and to look for any association of diet and lifestyle with the disease.

Citing Articles

Clinical and Hematological Manifestations of Systemic Lupus Erythematosus at Initial Presentation in a Tertiary Healthcare Center.

Bathina A, Chintada D, Yellu N, Vijayashree J, Khatija Begum M, Unnikrishnan P Cureus. 2025; 16(12):e75956.

PMID: 39830576 PMC: 11742627. DOI: 10.7759/cureus.75956.


Evaluation of disease activity in systemic lupus erythematosus using standard deviation of lymphocyte volume combined with red blood cell count and lymphocyte percentage.

Zhao J, Peng W, Wu S, Wang W Sci Rep. 2024; 14(1):22470.

PMID: 39341869 PMC: 11439007. DOI: 10.1038/s41598-024-72977-w.


Hematological factors associated with immunity, inflammation, and metabolism in patients with systemic lupus erythematosus: Data from a Zhuang cohort in Southwest China.

Lao X, Ma L, Ma Q, Ma Q, Yang Z, Guo L J Clin Lab Anal. 2020; 34(6):e23211.

PMID: 31978275 PMC: 7307337. DOI: 10.1002/jcla.23211.

References
1.
von Feldt J . Systemic lupus erythematosus. Recognizing its various presentations. Postgrad Med. 1995; 97(4):79, 83, 86 passim. View

2.
Carneiro J, Sato E . Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. J Rheumatol. 1999; 26(6):1275-9. View

3.
Bellomio V, Spindler A, Lucero E, Berman A, Santana M, Moreno C . Systemic lupus erythematosus: mortality and survival in Argentina. A multicenter study. Lupus. 2000; 9(5):377-81. View

4.
Bader-Meunier B, Armengaud J, Haddad E, Salomon R, Deschenes G, Kone-Paut I . Initial presentation of childhood-onset systemic lupus erythematosus: a French multicenter study. J Pediatr. 2005; 146(5):648-53. DOI: 10.1016/j.jpeds.2004.12.045. View

5.
McGrath H, Martinez-Osuna P, LEE F . Ultraviolet-A1 (340-400 nm) irradiation therapy in systemic lupus erythematosus. Lupus. 1996; 5(4):269-74. DOI: 10.1177/096120339600500405. View